Trial
NCT03696537
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Naoyuki G. Saito, M.D., Ph.D.
Collaborators
Indiana University
Condition
Acute Myeloid Leukemia
Intervention
Fludarabine
Why stopped
Extreme toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-09